
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition is in a strong position with promising pipeline and commercialization plans for its lead product, ZUNVEYL. The company has recorded impressive financial results and continues to advance in its clinical trials, providing important real-world evidence and expanding its commercial opportunities. The recent settlement agreement has streamlined royalty obligations and the addition of Bethany Sensenig as a director brings valuable experience and expertise to the company's leadership team.
Bears say
Alpha Cognition is facing challenges in achieving sales traction for ZUNVEYL, their primary product, due to pricing pressures and potential competition from both generic and branded products. Additionally, setbacks in clinical testing and a medium to long-term dilution risk pose significant risks to the company's prospects. With a total enterprise value of $520M and a price objective of $18 per share, it is evident that the negative outlook on Alpha Cognition's stock is driven by these fundamental risks and uncertainties.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares